One of the most interesting regulatory events last week is one that didn’t happen: Bristol Myers Squibb Company pulled an sBLA for Reblozyl ahead of its user fee goal date, avoiding a complete response letter.
Pediatrics were a common theme in the agency’s approvals. Ongoing efforts to improve treatment of pediatric organ transplant recipients resulted in new indications for Genentech, Inc.’s CellCept, while